Genfleet Therapeutics (Shanghai) Inc.
Genfleet Therapeutics (Shanghai) Inc.
Explore linked clinical trials.11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | pancreatic ductal adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT07678593 | |
| A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT07784374 | |
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT07846358 | |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-08-14 | NCT07262567 | |
| A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-08-10 | NCT07668752 | |
| GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-04-28 | NCT07554859 | |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2025-12-02 | NCT07259590 | |
| A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | Advanced Solid Tumors; KRAS G12D Mutations | Recruiting | Phase 1 / Phase 2 | 2025-11-20 | NCT06500676 | |
| A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, cancer, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, non-small cell lung carcinoma, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-09-30 | NCT07198321 | |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-12 | NCT06375733 | |
| A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia | Body Weight, Body Weight Changes, Cachexia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Thinness, Weight Loss, neoplasm | Recruiting | Phase 1 | 2025-06-05 | NCT06898255 |